Drug · Monoclonal Antibody

Tositumomab

CI-DRUG-00000707Explore in graph →CHEMBL1201604 Approved

Regulatory

Approvals (1)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as BEXXAR THERAPY (DIN 02270471) under ATC V10XA53 TOSITUMOMAB/IODINE (131 I) TOSITUMOMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 31, 2014	Apr 10, 2006	health-canada-dpd

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 15 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Withdrawn	Phase 2	0	0	0	3	1	CA	—	2004-04
Non-Hodgkin Lymphoma	Phase2	Phase 2	0	0	0	1	0	—	—	2004-04

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Curated evidence

Clinical evidence (0)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

Data not yet available

No curated evidence item mentions this therapy yet.

Clinical trials

Trials with this intervention (3)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–3 of 3 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00770224	S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma	completed	Phase 2	87	SWOG Cancer Research NetworkNETWORK	1	Aug 28, 2019	clinicaltrials
NCT00577629	Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma	completed

Molecule

Record

Kind: Monoclonal Antibody
Mechanism: B-lymphocyte antigen CD20 binding agent
Targets: 1 gene
Aliases: BEXXAR THERAPY, Tositumomab, Tositumomab component of bexxar

Data updated 2 days agoSource updated unknown

Identifiers

Codes (3)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	V10XA53	TOSITUMOMAB/IODINE (131 I) TOSITUMOMAB
DIN (Health Canada)	02270471	BEXXAR THERAPY
DPD drug code	75584